Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide

Oncology (Williston Park). 2015 Apr;29(4):265, 275.
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Antineoplastic Agents, Alkylating / adverse effects
  • Antineoplastic Agents, Alkylating / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chemotherapy, Adjuvant
  • Dacarbazine / adverse effects
  • Dacarbazine / analogs & derivatives*
  • Dacarbazine / therapeutic use
  • Evidence-Based Medicine
  • Glioma / drug therapy
  • Glioma / pathology
  • Humans
  • Lomustine / administration & dosage
  • Neoplasm Grading
  • Neoplasm Staging
  • Oligodendroglioma / drug therapy*
  • Oligodendroglioma / mortality
  • Oligodendroglioma / pathology
  • Procarbazine / administration & dosage
  • Prognosis
  • Radiotherapy, Adjuvant
  • Randomized Controlled Trials as Topic
  • Survival Analysis
  • Temozolomide
  • Treatment Outcome
  • Vincristine / administration & dosage

Substances

  • Antineoplastic Agents, Alkylating
  • Procarbazine
  • Vincristine
  • Lomustine
  • Dacarbazine
  • Temozolomide

Supplementary concepts

  • PCV protocol